Description
Book SynopsisThe guideline focuses specifically on evidence-based pharmacological treatments for AUD in outpatient settings and includes additional information on assessment and treatment planning, which are an integral part of using pharmacotherapy to treat AUD.
Table of ContentsGuideline Writing Group. Systematic Review Group. Steering Committee on Practice Guidelines. APA Assembly Liaisons. Acronyms/Abbreviations. Introduction. Rationale. Guideline Statement Summary. Guideline Statements and Implementation. Statement 1: Assessment of Substance Use. Statement 2: Use of Quantitative Behavioral Measures. Statement 3: Use of Physiological Biomarkers. Statement 4: Assessment of Co-Occurring Conditions. Statement 5: Determination of Initial Treatment Goals. Statement 6: Discussion of Legal Obligations. Statement 7: Review of Risks to Self and Others. Statement 8: Evidence-Based Treatment Planning. Statement 9: Naltrexone or Acamprosate. Statement 10: Disulfiram. Statement 11: Topiramate or Gabapentin. Statement 12: Antidepressants. Statement 13: Benzodiazepines. Statement 14: Pharmacotherapy in Pregnant or Breastfeeding Women. Statement 15: Acamprosate in Severe Renal Impairment. Statement 16: Acamprosate in Mild to Moderate Renal Impairment. Statement 17: Naltrexone in Acute Hepatitis or Hepatic Failure. Statement 18: Naltrexone with Concomitant Opioid Use. Statement 19: Naltrexone for Co-Occurring Opioid Use Disorder. Disclosures. Individuals and Organizations That Submitted Comments. Glossary of Terms. References. Appendixes: Review of Research Evidence.
